199 related articles for article (PubMed ID: 12374277)
21. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.
Daemen T; Regts J; Holtrop M; Wilschut J
Gene Ther; 2002 Jan; 9(2):85-94. PubMed ID: 11857066
[TBL] [Abstract][Full Text] [Related]
22. Human papillomavirus, it's genes...and cancer vaccines.
Steller MA
Cancer Cell; 2003 Jan; 3(1):7-8. PubMed ID: 12559170
[TBL] [Abstract][Full Text] [Related]
23. [Perspectives for the development of vaccines and immunotherapy against cervico-uterine cancer].
Guzmán-Rojas L; Alcocer-González JM; Madrid-Marina V
Salud Publica Mex; 1998; 40(1):38-46. PubMed ID: 9567657
[TBL] [Abstract][Full Text] [Related]
24. [Anti-papillomavirus immunologic response and natural history of cervical lesions].
Vinatier D; Dufour P
Contracept Fertil Sex; 1997 May; 25(5):339-47. PubMed ID: 9273102
[No Abstract] [Full Text] [Related]
25. Epidemiology: a tool for the study of human papillomavirus-related carcinogenesis.
Fisher SG
Intervirology; 1994; 37(3-4):215-25. PubMed ID: 7843932
[No Abstract] [Full Text] [Related]
26. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
[TBL] [Abstract][Full Text] [Related]
27. Transcriptome signature of irreversible senescence in human papillomavirus-positive cervical cancer cells.
Wells SI; Aronow BJ; Wise TM; Williams SS; Couget JA; Howley PM
Proc Natl Acad Sci U S A; 2003 Jun; 100(12):7093-8. PubMed ID: 12756294
[TBL] [Abstract][Full Text] [Related]
28. Multiple mechanisms underlie HLA dysregulation in cervical cancer.
Brady CS; Bartholomew JS; Burt DJ; Duggan-Keen MF; Glenville S; Telford N; Little AM; Davidson JA; Jimenez P; Ruiz-Cabello F; Garrido F; Stern PL
Tissue Antigens; 2000 May; 55(5):401-11. PubMed ID: 10885560
[TBL] [Abstract][Full Text] [Related]
29. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.
Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E
Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645
[TBL] [Abstract][Full Text] [Related]
30. T-helper epitopes identified within the E6 transforming protein of cervical cancer-associated human papillomavirus type 16.
Azoury-Ziadeh R; Herd K; Fernando GJ; Frazer IH; Tindle RW
Viral Immunol; 1999; 12(4):297-312. PubMed ID: 10630789
[TBL] [Abstract][Full Text] [Related]
31. The roles of the human major histocompatibility complex and human papillomavirus infection in cervical intraepithelial neoplasia and cervical cancer.
Odunsi KO; Ganesan TS
Clin Oncol (R Coll Radiol); 1997; 9(1):4-13. PubMed ID: 9039807
[No Abstract] [Full Text] [Related]
32. Immunobiology of papillomavirus infections.
Stanley MA
J Reprod Immunol; 2001; 52(1-2):45-59. PubMed ID: 11600177
[No Abstract] [Full Text] [Related]
33. [Recombinant therapeutic vaccines against cancer of the uterine cervix].
Berumen J; Villegas N
Salud Publica Mex; 1997; 39(4):288-97. PubMed ID: 9381250
[TBL] [Abstract][Full Text] [Related]
34. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.
Liu DW; Tsao YP; Kung JT; Ding YA; Sytwu HK; Xiao X; Chen SL
J Virol; 2000 Mar; 74(6):2888-94. PubMed ID: 10684306
[TBL] [Abstract][Full Text] [Related]
35. [Papillomavirus infections and cervical tumorigenesis].
Kiyono T
Gan To Kagaku Ryoho; 2010 Feb; 37(2):227-31. PubMed ID: 20235389
[No Abstract] [Full Text] [Related]
36. Recent studies attempt to clarify relationship between oral cancer and human papillomavirus.
Erdmann J
J Natl Cancer Inst; 2003 May; 95(9):638-9. PubMed ID: 12734307
[No Abstract] [Full Text] [Related]
37. Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia.
Schiffman MH; Castle P
J Natl Cancer Inst; 2003 Mar; 95(6):E2. PubMed ID: 12644550
[No Abstract] [Full Text] [Related]
38. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
[TBL] [Abstract][Full Text] [Related]
39. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines.
Chen CH; Wang TL; Hung CF; Pardoll DM; Wu TC
Vaccine; 2000 Apr; 18(19):2015-22. PubMed ID: 10706963
[TBL] [Abstract][Full Text] [Related]
40. Immunity to human papillomavirus-associated cervical neoplasia.
Stern PL
Adv Cancer Res; 1996; 69():175-211. PubMed ID: 8791682
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
